BACKGROUND: The metalloproteinases ADAM10 and ADAM17 are involved in various diseases: neurodegeneration, cancer and inflammation. OBJECTIVE: The inhibition of these proteases is a promising target in the treatment of inflammation and cancer. METHODS AND RESULTS: In this study, we present an improved synthesis of the ADAM10 reference inhibitor GI254023X with a higher overall yield, enhanced detection ability and increased acid stability, providing easier handling. CONCLUSION: This upscaled synthesis, free of diastereomeric intermediates, ensures single-batch identity, thus warranting its reproducibility in further biological investigations.
No takes yet. Share an insight, caveat, or question.
Hoettecke et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: